PMID- 26162700
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20200711
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 764
DP  - 2015 Oct 5
TI  - Central injection of CDP-choline suppresses serum ghrelin levels while increasing 
      serum leptin levels in rats.
PG  - 264-270
LID - S0014-2999(15)30141-2 [pii]
LID - 10.1016/j.ejphar.2015.07.014 [doi]
AB  - In this study we aimed to test central administration of CDP-choline on serum 
      ghrelin, leptin, glucose and corticosterone levels in rats. 
      Intracerebroventricular (i.c.v.) 0.5, 1.0 and 2.0 micromol CDP-choline and saline 
      were administered to male Wistar-Albino rats. For the measurement of serum leptin 
      and ghrelin levels, blood samples were obtained baseline and at 5, 15, 30, 60 and 
      120 min following i.c.v. CDP-choline injection. Equimolar doses of i.c.v. choline 
      (1.0 micromol) and cytidine (1.0 micromol) were administered and measurements were 
      repeated throughout the second round of the experiment. Atropine (10 microg) and 
      mecamylamine (50 microg) were injected intracerebroventricularly prior to CDP-choline 
      and measurements repeated in the third round of the experiment. After 1 micromol 
      CDP-choline injection, serum ghrelin levels were suppressed significantly at 60 
      min (P=0.025), whereas serum leptin levels were increased at 60 and 120 min 
      (P=0.012 and P=0.017 respectively). CDP-choline injections also induced a dose- 
      and time-dependent increase in serum glucose and corticosterone levels. The 
      effect of choline on serum leptin and ghrelin levels was similar with CDP-choline 
      while no effect was seen with cytidine. Suppression of serum ghrelin levels was 
      eliminated through mecamylamine pretreatment while a rise in leptin was prevented 
      by both atropine and mecamylamine pretreatments. In conclusion; centrally 
      injected CDP-choline suppressed serum ghrelin levels while increasing serum 
      leptin levels. The observed effects following receptor antagonist treatment 
      suggest that nicotinic receptors play a role in suppression of serum ghrelin 
      levels,whereas nicotinic and muscarinic receptors both play a part in the 
      increase of serum leptin levels.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Kiyici, Sinem
AU  - Kiyici S
AD  - Uludag University Medical Faculty, Department of Pharmacology, Bursa, Turkey. 
      Electronic address: drsinemkiyici@gmail.com.
FAU - Basaran, Nesrin Filiz
AU  - Basaran NF
AD  - Uludag University Medical Faculty, Department of Pharmacology, Bursa, Turkey. 
      Electronic address: nesfiliz@gmail.com.
FAU - Cavun, Sinan
AU  - Cavun S
AD  - Uludag University Medical Faculty, Department of Pharmacology, Bursa, Turkey. 
      Electronic address: scavun@gmail.com.
FAU - Savci, Vahide
AU  - Savci V
AD  - Uludag University Medical Faculty, Department of Pharmacology, Bursa, Turkey. 
      Electronic address: vsavci@uludag.edu.tr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150707
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Blood Glucose)
RN  - 0 (Ghrelin)
RN  - 0 (Leptin)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Nicotinic Antagonists)
RN  - 0 (Receptors, Muscarinic)
RN  - 0 (Receptors, Nicotinic)
RN  - 536BQ2JVC7 (Cytidine Diphosphate Choline)
RN  - 6EE945D3OK (Mecamylamine)
RN  - 7C0697DR9I (Atropine)
RN  - W980KJ009P (Corticosterone)
SB  - IM
MH  - Animals
MH  - Atropine/pharmacology
MH  - Blood Glucose/analysis
MH  - Corticosterone/blood
MH  - Cytidine Diphosphate Choline/*pharmacology
MH  - Ghrelin/*blood
MH  - Injections
MH  - Leptin/*blood
MH  - Male
MH  - Mecamylamine/pharmacology
MH  - Muscarinic Antagonists/pharmacology
MH  - Nicotinic Antagonists/pharmacology
MH  - Rats, Wistar
MH  - Receptors, Muscarinic/metabolism
MH  - Receptors, Nicotinic/metabolism
OTO - NOTNLM
OT  - CDP-choline
OT  - Ghrelin
OT  - Leptin
EDAT- 2015/07/15 06:00
MHDA- 2016/07/29 06:00
CRDT- 2015/07/12 06:00
PHST- 2015/06/05 00:00 [received]
PHST- 2015/07/03 00:00 [revised]
PHST- 2015/07/06 00:00 [accepted]
PHST- 2015/07/12 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
AID - S0014-2999(15)30141-2 [pii]
AID - 10.1016/j.ejphar.2015.07.014 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2015 Oct 5;764:264-270. doi: 10.1016/j.ejphar.2015.07.014. Epub 
      2015 Jul 7.